natgillin/translations-raw huggingface dataset:
Non-clinical data on emtricitabine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. 
Neklinički podaci o emtricitabinu ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenosti, reproduktivne i razvojne toksičnosti.
Elvitegravir (simultaneous administration): 
Elvitegravir (primjena u isto vrijeme):
At baseline, 80 patients (33%) had eGFRCG < 50 mL/min and 162 patients had eGFRCG ≥ 50 mL/min. 
Na početku je 80 bolesnika (33%) imalo eGFRCG < 50 ml/min, a 162 bolesnika su imala eGFRCG ≥ 50 ml/min.
Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV-1 RT. 
Smanjena osjetljivost na emtricitabin povezana je s M184V/I mutacijama u HIV-1 RT.
Inhibition of integrase prevents the integration of HIV-1 deoxyribonucleic acid (DNA) into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. 
Inhibicija integraze sprječava integraciju HIV-1 deoksiribonukleinske kiseline (DNK) u genomski DNK domaćina, blokirajući formiranje provirusa HIV-1 i propagaciju virusne infekcije.
Some patients taking combination antiretroviral medicines such as Genvoya may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). 
Neki bolesnici koji uzimaju kombinirane antiretrovirusne lijekove kao što je Genvoya mogu razviti bolest kostiju koja se zove osteonekroza (odumiranje koštanog tkiva prouzrokovano gubitkom prokrvljenosti kosti).
• suicidal thoughts and suicide attempt (in patients who have had depression or mental health problems before), depression 
• suicidalne misli i pokušaj suicida (u bolesnika koji su prethodno bolovali od depresije ili neke druge psihijatrijske bolesti), depresija
In these 2 patients, no amino acid substitutions associated with resistance to any of the components of Genvoya were identified in HIV-1 or HBV. 
U ta 2 bolesnika, supstitucije aminokiselina povezane s rezistencijom na bilo koji sastojak lijeka Genvoya nisu utvrđene u HIV 1 ili HBV.
Additional integrase mutations observed in cell culture selection included H51Y, F121Y, S147G, S153Y, E157Q, and R263K. 
Dodatne mutacije integraze zapažene u izdvojenoj staničnoj kulturi bile su H51Y, F121Y, S147G, S153Y, E157Q i R263K.
• If you are allergic to elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide or any of the other ingredients of this medicine (listed in section 6 of this leaflet). 
• ako ste alergični na elvitegravir, kobicistat, emtricitabin, tenofoviralafenamid ili neki drugi sastojak ovog lijeka (naveden u dijelu 6 ove upute).
Therefore, information regarding drug-drug interactions with other antiretroviral products (including protease inhibitors [PIs] and non-nucleoside reverse transcriptase inhibitors [NNRTIs]) is not provided (see section 4.4). 
Stoga nisu navedene informacije o interakcijama lijeka s drugim antiretrovirusnim lijekovima (uključujući IP i nenukleozidne inhibitore reverzne transkriptaze [NNRTI]) (vidjeti dio 4.4).
As elvitegravir and cobicistat are highly bound to plasma proteins, it is unlikely that they would be significantly removed by haemodialysis or peritoneal dialysis. 
Budući da su elvitegravir i kobicistat u visokom postotku vezani za proteine plazme, nije vjerojatno da će se značajno ukloniti hemodijalizom ili peritonejskom dijalizom.
However, tenofovir disoproxil reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses. 
Ipak, tenofovirdizoproksil smanjio je indeks preživljenja i težinu mladunčadi u perinatalnim i postnatalnim ispitivanjima toksičnosti pri dozama toksičnim za majku.
Most HIV-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir developed resistance mutations to both emtricitabine and elvitegravir. 
Većina HIV-1 izolata od bolesnika iz obje skupine koji su razvili mutacije povezane s rezistencijom na elvitegravir, razvili su i mutacije povezane s rezistencijom i na emtricitabin i na elvitegravir.
Through 144 weeks of treatment, no subject discontinued Genvoya due to a treatment-emergent renal adverse event compared with 12 subjects who discontinued E/C/F/TDF (p < 0.001). 
Tijekom 144 tjedna liječenja, nijedan ispitanik nije prekinuo primjenu lijeka Genvoya zbog štetnih događaja povezanih s bubrezima nastalih tijekom liječenja, u usporedbi s 12 ispitanika koji su prekinuli primjenu E/C/F/TDF-a (p < 0,001).
Signs of osteonecrosis are: joint stiffness joint aches and pains (especially of the hip, knee and shoulder) difficulty with movement 
Znakovi osteonekroze su: ukočenost zglobova, tupi bolovi i probadanje u zglobovima (osobito u kuku, koljenu i ramenu), poteškoće pri kretanju.
If you are taking an antacid such as aluminium/magnesium hydroxide or a multivitamin supplement, take it at least 4 hours before or at least 4 hours after Genvoya. 
Ako uzimate antacid, kao što je aluminijev/magnezijev hidroksid, ili multivitaminski dodatak, uzmite ga najmanje 4 sata prije ili najmanje 4 sata nakon uzimanja lijeka Genvoya.
Ex vivo rabbit studies and in vivo dog studies suggest that cobicistat has a low potential for QT prolongation, and may slightly prolong the PR interval and decrease left ventricular function at concentrations at least 11-fold higher than the human exposure at the recommended 150 mg daily dose. 
Ex vivo ispitivanja na kunićima i in vivo ispitivanja na psima navode da kobicistat ima niski potencijal za prolongaciju QT-a, te može malo produljiti interval PR-a i smanjiti funkciju lijeve klijetke pri koncentracijama najmanje 11 puta većim od humane izloženosti na preporučenoj dnevnoj dozi od 150 mg.
Cobicistat increases serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function. 
Kobicistat uzrokuje porast serumskog kreatinina zbog inhibicije tubularne sekrecije kreatinina bez utjecaja na glomerularnu funkciju bubrega.
• cholesterol lowering medicines, such as: 
• lijekove koji snižavaju kolesterol, kao što su:
Table 7: Changes in pharmacokinetic parameters from the IMPAACT P1026s study for elvitegravir and cobicistat in women receiving cobicistat and elvitegravir-containing regimens during the second and third trimesters of pregnancy compared to paired postpartum data 
Tablica 7: Promjene farmakokinetičkih parametara u ispitivanju IMPAACT P1026s za elvitegravir i kobicistat u žena koje su primale režime koji sadrže kobicistat i elvitegravir tijekom drugog i trećeg tromjesečja trudnoće u usporedbi s uparenim podacima iz postpartalnog razdoblja
Genvoya is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows: 
Genvoya je indicirana za liječenje osoba zaraženih virusom humane imunodeficijencije tipa 1 (HIV-1) bez ijedne poznate mutacije povezane s rezistencijom na skupinu inhibitora integraze, emtricitabin ili tenofovir i to:
Concentrations of other benzodiazepines, including diazepam, may be increased when administered with Genvoya. 
Koncentracije drugih benzodiazepina, uključujući diazepam, mogu biti povećane kada se primjenjuju s lijekom Genvoya.
If you are on dialysis, take your daily dose of Genvoya following completion of dialysis. 
Ako ste na dijalizi, svoju dnevnu dozu lijeka Genvoya uzmite nakon završetka postupka dijalize.
 If you are taking an antacid or a multivitamin supplement, take it at least 4 hours before or at least 4 hours after Genvoya. 
Ako uzimate antacid ili multivitaminski dodatak, uzmite ga najmanje 4 sata prije ili najmanje 4 sata nakon uzimanja lijeka Genvoya.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.4). 
Autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa) također su zabilježeni; međutim, prijavljeno vrijeme do nastupa poremećaja više varira i ti događaji mogu se pojaviti puno mjeseci nakon početka liječenja (vidjeti dio 4.4).
There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. 
Postoje izvješća o poremećaju funkcije mitohondrija kod HIV negativne dojenčadi koja je bila in utero i/ili postnatalno izložena analozima nukleozida; ova izvješća su se pretežno odnosila na liječenje režimima koji su sadržavali zidovudin.
Genvoya (n = 866) 
(n = 866)
Renal excretion of intact tenofovir alafenamide is a minor pathway with < 1% of the dose eliminated in urine. 
Bubrežna ekskrecija nerazgrađenog tenofoviralafenamida je manji put izlučivanja kojim se eliminira < 1% doze u urinu.
Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). 
Elvitegravir je inhibitor prijenosa lanca HIV-1 integraze (INSTI).
At baseline, median eGFR was 56 mL/min. 
Medijan eGFR na početku iznosio je 56 ml/min.
In patients with severe hepatic impairment, total plasma concentrations of tenofovir alafenamide and tenofovir are lower than those seen in subjects with normal hepatic function. 
U bolesnika s teškim oštećenjem jetre, ukupne koncentracije tenofoviralafenamida i tenofovira u plazmi niže su od onih opaženih u ispitanika s normalnom funkcijom jetre.
Green, capsule-shaped, film-coated tablet of dimensions 19 mm x 8.5 mm, debossed with “GSI” on one side of the tablet and “510” on the other side of the tablet. 
Zelena filmom obložena tableta u obliku kapsule veličine 19 mm x 8,5 mm, s utisnutom oznakom „GSI“ na jednoj strani tablete i „510“ na drugoj strani tablete.
The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (~4% of dose). 
Biotransformacija emtricitabina uključuje oksidaciju tiolnog dijela molekule pri čemu nastaju 3'-sulfoksid diastereomeri (~9% doze), i konjugaciju s glukuronskom kiselinom, pri čemu nastaje 2'-O-glukuronid (~4% doze).
Polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol (E1521), talc (E553b), indigo carmine aluminium lake (E132), iron oxide yellow (E172). 
Poli(vinilni alkohol) (E1203), titanijev dioksid (E171), poli(etilenglikol) (E1521), talk (E553b), boja indigo carmine aluminium lake (E132), željezov oksid žuti (E172)
The pharmacokinetics of emtricitabine have not been studied in patients with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited. 
Farmakokinetika emtricitabina nije ispitana u bolesnika s oštećenjem funkcije jetre; međutim emtricitabin se neznatno metabolizira putem enzima jetre, pa bi učinak oštećenja funkcije jetre morao biti ograničen.
Thirteen percent of the dose was recovered in the urine as three putative metabolites. 
Trinaest posto doze izolirano je u urinu u obliku tri putativna metabolita.
If the combination is needed, the recommended dose of rifabutin is 150 mg 3 times per week on set days (for example MondayWednesday-Friday). 
Ako je kombinacija ipak potrebna, preporučena doza rifabutina je 150 mg triput tjedno u određene dane (npr.
ANTACIDS 
ANTACIDI
• In adults and adolescents aged from 12 years and with body weight at least 35 kg 
• odraslih i adolescenata u dobi od 12 godina i starijih, s tjelesnom težinom od najmanje 35 kg
Interaction not studied with any of the components of Genvoya. 
Interakcija nije ispitana ni s jednom komponentom lijeka Genvoya.
In clinical trials, the incidence of SAEs related to suicide for Genvoya was 0.6% (26/4137 subjects), therefore, the frequency proposed is “uncommon”. 
U kliničkim ispitivanjima je incidencija ozbiljnih štetnih događaja povezanih sa suicidom za lijek Genvoya iznosila 0,6% (26/4137 ispitanika) te je stoga predložena učestalost „manje često“.
No special hazard for humans was revealed in conventional studies of carcinogenic potential and toxicity to reproduction and development. 
Nije otkriven poseban rizik za ljude na temelju konvencionalnih ispitivanja kancerogenosti te reproduktivne i razvojne toksičnosti.
When your supply of Genvoya starts to run low, get more from your doctor or pharmacist. 
Kad Vam se smanji zaliha lijeka Genvoya, nabavite još lijeka od liječnika ili ljekarnika.
• antidepressants, used to treat depression: medicines containing trazodone or escitalopram 
• antidepresive, primjenjuju se za liječenje depresije: lijekovi koji sadržavaju trazodon ili escitalopram
If you accidentally take more than the recommended dose of Genvoya you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects). 
Ako slučajno uzmete više od preporučene doze lijeka Genvoya, može Vam se povećati rizik od mogućih nuspojava ovog lijeka (pogledajte dio 4, Moguće nuspojave).
Tenofovir is eliminated from the body by the kidneys by both glomerular filtration and active tubular secretion. 
Tenofovir se eliminira iz tijela bubrezima putem glomerularne filtracije i aktivne tubularne sekrecije.
Elderly No dose adjustment of Genvoya is required in elderly patients (see sections 5.1 and 5.2). 
Nije potrebna prilagodba doze lijeka Genvoya u starijih bolesnika (vidjeti dijelove 5.1 i 5.2).
Genvoya is a single tablet for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults, adolescents and children 6 years of age and older, who weigh at least 25 kg. Genvoya reduces the amount of HIV in your body. 
Genvoya je jedna tableta za liječenje infekcije virusom humane imunodeficijencije 1 (HIV-1) u odraslih, adolescenata i djece u dobi od 6 godina i starijih, koji imaju tjelesnu težinu od najmanje 25 kg.
Genvoya should be avoided in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not on chronic haemodialysis, as the safety of Genvoya has not been established in these populations. 
Primjenu lijeka Genvoya potrebno je izbjegavati u bolesnika s procijenjenim CrCl ≥ 15 ml/min i < 30 ml/min, ili < 15 ml/min koji nisu na kroničnoj hemodijalizi, jer sigurnost primjene lijeka Genvoya u ovih populacija nije ustanovljena.
Genvoya can cause dizziness. 
Genvoya može uzrokovati omaglicu.
There are no data on fertility from the use of Genvoya in humans. 
Plodnost Nema podataka o plodnosti pri primjeni lijeka Genvoya u ljudi.
Talk to your doctor if you are taking: 
Druge vrste lijekova: Obavijestite svog liječnika ako uzimate:
The use of Genvoya in children aged 5 years or under has not yet been studied. 
Primjena lijeka Genvoya u djece u dobi od 5 godina i mlađoj još nije ispitana.
As such, tenofovir alafenamide exposures following administration of Genvoya are not expected to be further increased when used in combination with another P-gp and/or BCRP inhibitor (e.g., ketoconazole). 
Zbog toga se ne očekuje daljnji porast izloženosti tenofoviralafenamidu nakon primjene lijeka Genvoya u kombinaciji s drugim P-gp i/ili BCRP inhibitorom (npr. ketokonazolom).
Based on drug-drug interaction studies conducted with Genvoya or the components of Genvoya, no clinically significant drug-drug interactions have been either observed or are expected between the components of Genvoya and the following medicinal products: entecavir, famciclovir, ribavirin, famotidine, and omeprazole. 
Na osnovi ispitivanja interakcija lijekova provedenih s lijekom Genvoya ili komponentama lijeka Genvoya nisu zabilježene nikakve klinički značajne interakcije lijekova niti se očekuju između komponenti lijeka Genvoya i sljedećih lijekova: entekavira, famciklovira, ribavirina, famotidina i omeprazola.
The safety and efficacy of Genvoya in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established. 
Sigurnost i djelotvornost primjene lijeka Genvoya u bolesnika istodobno zaraženih virusom HIV-1 i virusom hepatitisa C (HCV) nisu ustanovljene.
• cobicistat, a booster (pharmacokinetic enhancer) of the effects of elvitegravir 
• kobicistat, pojačivač (farmakokinetički pojačivač) učinaka elvitegravira
Patients with end stage renal disease on chronic haemodialysis 
Bolesnici sa završnim stadijem bolesti bubrega na kroničnoj hemodijalizi
• If you notice 18 hours or more after the time you usually take Genvoya, then do not take the missed dose. 
• Ako to primijetite kada je prošlo 18 sati ili više od vremena kada obično uzimate lijek Genvoya, onda nemojte uzeti propuštenu dozu.
Other effects that may be seen during HIV treatment 
Druge nuspojave koje se mogu javiti tijekom liječenja HIV-a
Cobicistat and tenofovir alafenamide are not inhibitors of human UGT1A1 in vitro. 
Kobicistat i tenofoviralafenamid nisu inhibitori ljudske UGT1A1 in vitro.
An assessment of benefit/risk ratio is recommended to justify use of voriconazole with Genvoya. 
Procjena omjera koristi/rizika preporučuje se radi opravdanja primjene vorikonazola s lijekom Genvoya.
Genvoya film-coated tablets are green, capsule-shaped tablets, debossed on one side with “GSI” and the number “510” on the other side of the tablet. 
Genvoya filmom obložene tablete su zelene tablete u obliku kapsula s utisnutom oznakom „GSI“ na jednoj strani i brojem „510“ na drugoj strani tablete.
One patient in the Genvoya group (1 of 22 [4.5%]) and 2 patients in the E/C/F/TDF group (2 of 20 [10%]) had reduced susceptibility to tenofovir. 
Jedan bolesnik u skupini liječenoj lijekom Genvoya (1 od 22 [4,5%]) i 2 bolesnika u skupini koja je primala E/C/F/TDF (2 od 20 [10%]) imali su smanjenu osjetljivost na tenofovir.
Co-administration with CYP3A-metabolised corticosteroids is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid effects. 
Ne preporučuje se istodobna primjena s kortikosteroidima koji se metaboliziraju putem CYP3A, osim kada potencijalna korist za bolesnika nadmašuje rizik, a u tom slučaju je bolesnike potrebno pratiti radi eventualnih sistemskih učinaka kortikosteroida.
Following administration of tenofovir alafenamide, plasma [14C]-radioactivity showed a time-dependent profile with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period. 
Nakon primjene tenofoviralafenamida, [14C]-radioaktivnost u plazmi pokazala je profil ovisan o vremenu s tenofoviralafenamidom kao najzastupljenijim u prvih nekoliko sati i mokraćnom kiselinom u preostalom razdoblju.
Cobicistat is also a weak CYP2D6 inhibitor and is metabolised, to a minor extent, by CYP2D6. 
Kobicistat je također slab inhibitor CYP2D6 i u manjoj ga mjeri metabolizira CYP2D6.
Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia. 
Relevantni primjeri obuhvaćaju citomegalovirusni retinitis, generalizirane i/ili žarišne mikobakterijske infekcije, te upalu pluća uzrokovanu s Pneumocystis jirovecii.
For elvitegravir, Cmax and AUC increased 22% and 36% with a light meal, and 56% and 91% with a high-fat meal, relative to fasting conditions. 
Vrijednosti Cmax i AUC za elvitegravir povećale su se 22%, odnosno 36% s laganim obrokom, a s visokomasnim obrokom 56%, odnosno 91% u odnosu na stanje natašte.
Eighty-six percent of patients (62/72) were HBV suppressed (HBV DNA < 29 IU/mL) and 42% (30/72) were HBeAg positive at baseline. 
Osamdeset šest posto bolesnika (62/72) imalo je supresiju HBV-a (HBV DNA < 29 IU/ml) i 42% (30/72) bilo je HBeAg pozitivno pri ishodištu.
Viruses expressing the T66I/A mutations maintain susceptibility to raltegravir, while most other patterns showed reduced susceptibility to raltegravir. 
Virusi koji izražavaju mutacije T66I/A zadržavaju osjetljivost na raltegravir, dok većina drugih uzoraka pokazuje smanjenu osjetljivost na raltegravir.
Cobicistat exposures were unaffected by a light meal and although there was a modest decrease of 24% and 18% in Cmax and AUC respectively with a high-fat meal, no difference was observed in its pharmacoenhancing effect on elvitegravir. 
Lagani obrok nije utjecao na izloženost kobicistatu, a iako je došlo do umjerenog pada vrijednosti Cmax i AUC od 24%, odnosno 18% s visokomasnim obrokom, nikakva razlika nije zapažena u njegovom pojačavajućem farmakološkom učinku na elvitegravir.
• If you are intolerant to lactose (see Genvoya contains lactose later in this section). 
• Ako ne podnosite laktozu (u nastavku teksta potražite Genvoya sadrži laktozu).
No dose adjustment of clarithromycin is required. 
Nije potrebna prilagodba doze klaritromicina.
When administering with Genvoya, the maximum daily dose of ketoconazole should not exceed 200 mg per day. 
Prilikom primjene s lijekom Genvoya maksimalna dnevna doza ketokonazola ne smije biti veća od 200 mg na dan.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment. 
Autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa) također su zabilježeni u stanju imunološke reaktivacije; međutim, prijavljeno vrijeme do nastupa poremećaja više varira i ti događaji mogu se pojaviti puno mjeseci nakon početka liječenja.
Both elvitegravir and cobicistat are primarily metabolised and eliminated by the liver. 
Elvitegravir i kobicistat prvenstveno se metaboliziraju i eliminiraju kroz jetru.
Start with the lowest possible dose of atorvastatin with careful monitoring upon co-administration with Genvoya. 
Potrebno je započeti s najnižom mogućom dozom atorvastatina uz pažljivo praćenje nakon istodobne primjene lijeka Genvoya.
The safety profile of Genvoya in patients with mild to moderate renal impairment was similar to that in patients with normal renal function (see section 5.1). 
Sigurnosni profil lijeka Genvoya u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega bio je sličan onome u bolesnika s normalnom funkcijom bubrega (vidjeti dio 5.1).
diarrhoea, vomiting, abdominal pain, flatulence 
proljev, povraćanje, bol u abdomenu, flatulencija
Co-administration is contraindicated with medicinal products that are strong inducers of CYP3A due to the potential for loss of virologic response and possible resistance to Genvoya. 
Kontraindicirana je istodobna primjena s lijekovima koji su snažni induktori CYP3A zbog mogućeg gubitka virološkog odgovora i moguće rezistencije na lijek Genvoya.
Following oral administration with food in HIV-1 infected patients, peak plasma concentrations were observed approximately 4 hours post-dose for elvitegravir, 3 hours post-dose for cobicistat, 3 hours post-dose for emtricitabine, and 1 hour post-dose for tenofovir alafenamide. 
Nakon peroralne primjene s hranom u bolesnika zaraženih virusom HIV-1, vršne koncentracije u plazmi zapažene su otprilike 4 sata nakon doziranja elvitegravira, 3 sata nakon doziranja kobicistata, 3 sata nakon doziranja emtricitabina i 1 sat nakon doziranja tenofoviralafenamida.
Medicinal products that are highly dependent on CYP3A metabolism and have high first pass metabolism are the most susceptible to large increases in exposure when co-administered with cobicistat (see “Concomitant use contraindicated” and section 4.3). 
Lijekovi koji su jako ovisni o metabolizmu putem CYP3A i imaju izražen metabolizam prvog prolaska najpodložniji su velikim povećanjima izloženosti kada se primjenjuju istodobno s kobicistatom (vidjeti „Kontraindicirana istodobna primjena“ i dio 4.3).
5 This study was conducted using Genvoya. 
5 To je ispitivanje provedeno pomoću lijeka Genvoya.
What you need to know before you take Genvoya Do not take Genvoya: 
Što morate znati prije nego počnete uzimati lijek Genvoya Nemojte uzimati lijek Genvoya: